Medicines for Malaria Venture (MMV), a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999.

In January 2009, Novartis and Medicines for Malaria Venture (MMV) launched Coartem Dispersible, the first artemisinin-based combination therapy developed specifically for children suffering from malaria.

Lady Chalker Lynda Chalker is a former Chairman of the Medicines for Malaria Venture, a not-for-profit foundation dedicated to reducing the burden of malaria in disease endemic countries.

It was discovered by US and European scientists who were coordinated by the Medicines for Malaria Venture (MMV).

Three nonprofit organizations (the Drugs for Neglected Diseases Initiative, iOWH, and the Medicines for Malaria Venture) are actively working to support various stages of the drug-development pipeline.

Medicines for Malaria Venture (MMV) [1] - for information on the largest-ever portfolio of over 50 antimalarial projects, working in collaboration with over 100 pharmaceutical, academic, and endemic-country partners in 38 countries.

July 2012 saw the release of a new malaria data service, sponsored by the Medicines for Malaria Venture (MMV), aimed at researchers around the globe.

The Gates Foundation alone has given about $300 million in the last few years to the Medicines for Malaria Venture, the Malaria Vaccine Initiative and to promising innovations like Dr. Keasling's.

In 2011, FIND was recognized as an "Other International Organization" by the Swiss Government, alongside DNDi and Medicines for Malaria Venture.

MMV.org (Medicine for Malaria Venture)